Mr Richard Nagle
Chief Executive Officer
Mr Richard Nagle (Chief Executive Officer) is a life sciences entrepreneur with over 25 years’ experience in the pharmaceutical industry across the US, Europe and Australasia. He was part of the early Innovex HQ team, at the forefront of outsourcing services, where he built and managed the development of large pharmaceutical sales forces, CRA’s and marketing. Innovex was acquired by Quintiles. He was Commercial Director of Walsh/PMSI, which was acquired by IMS Health, the leading supplier of strategic research and data to the pharmaceutical industry.
Moving into drug development, he became Commercial Director of Adelphi Group, responsible for the Strategic Product Development Consultancy, advising global pharmaceutical companies. He was CEO of Cardiac Alert which was acquired by Quintiles. He developed a new drug delivery system for Alza Corporation. The product was subsequently sold to Bayer and is now sold as Duragesic™. He co-founded Melee Venture Management which founded and developed a pain management business, an agri-biotech venture which placed extracted silica into depleted soils in commercial farms, two leading scientifically based cosmetics companies and a wound healing group, Wound Solutions. He joined Metellus, a Swiss-based investment firm, as Partner in 2014, joining the Board of Immune Regulation (formerly Peptinnovate) in 2015.
Dr. Roly Foulkes
Chief Scientific Officer (CSO)
Dr. Foulkes gained his PhD in cardiovascular pharmacology at the University of Nottingham before working as a post-doc at the University of Milan. He joined Celltech in 1987 working on both small molecules and biologics becoming head of Pharmacology and Drug Metabolism and Pharmacokinetics covering immunology and oncology projects. He held a number of executive positions at Celltech (and at UCB following the acquisition of Celltech) and was the Therapeutic area Head for Immunology from 2004-2012, responsible for strategy and the portfolio.
Since 2012 Roly has worked as a consultant to small start-ups and small Pharma companies, successfully advising on a wide range of strategic and operational issues as well as fund raising.
Mr David Beadle
Chief Business Officer
David Beadle has over 25 years’ experience in the healthcare and finance industries and brings a wealth of knowledge in investment banking, finance and life sciences. David started his career working in the pharmaceutical industry for Schwarz Pharma and Schering AG in marketing and strategic development, where he was part of the global development group for oncology.
He then moved to investment banking where he built and led highly ranked healthcare equity research teams both globally and across Europe. He first joined Hoare-Govett and then moved to UBS AG investment bank where he was a Managing Director in the equities division. He was a leading and highly ranked equity research analyst in the healthcare sector for over 10 years. At UBS, David was the lead analyst on several corporate finance projects, including IPOs and M&A.
David has been a non-executive Director to two successful companies in the healthcare and biotechnology space and has consulted for many others regarding scientific, corporate finance and business development strategies. David was a founding partner of Napa Capital, a corporate finance advisory company, working with several clients regarding financing projects and corporate strategy.
Dr. Clare Burgess
Chief Operating Officer
Dr. Clare Burgess (Chief Operating Officer) is a pharmacologist who has worked in the pharmaceutical industry for 24 years across a wide range of therapeutic areas. She has a broad knowledge of drug development from candidate selection through to Phase III clinical trials gained through roles at GSK (and legacy companies) as a Toxicology Study Director, Clinical Development Director and Global Project Leader, leading multidisciplinary teams across the USA and Europe. At GSK, Clare was the Clinical leader for an atypical antipsychotic drug taking it from FTIH to Phase 2b. Within this project she completed a Phase 1b safety study in schizophrenia patients (a first at GSK) and delivered one of the first fully adaptive proof of concept studies in patients with acute schizophrenia. Clare also designed and gained EMA endorsement for a first of its kind, thorough QTc study in patients with chronic schizophrenia (an industry first). Prior to joining Immune Regulation (formerly Peptinnovate) as COO, Clare was Head of Development and then COO at Helperby Therapeutics.
Mr. Michael Albisser
Chief Financial Officer
Michael Albisser (Chief Financial Officer) was previously acting CFO of the controlling unit of a multi-billion dollar single Family Office in Europe, before joining Metellus as a Partner. Extensive experience in accounting, controlling and reporting of investments in all asset classes, including Private Equity, Hedge Funds, industrial and agricultural ventures.
Dr. Ann Simon
Director of Corporate Affairs
Dr Ann Simon has successful track record in the life sciences and technology sectors and has worked with numerous companies providing support and advice in the areas of finance, strategic planning and funding to development-stage life sciences companies. At Immune Regulation, Ann has responsibility for legal, corporate governance and financial planning.
She spent more than a decade in corporate finance advisory at Cazenove & Co. in City of London advising clients ranging from start-ups to FTSE100 companies. She has managed IPOs (London full list and AIM), corporate acquisitions and trade sales and fund raisings in the public and private markets.
Over the past 15 years she has held numerous executive and non-executive roles including chairman of OBS Medical and Chief Financial Officer of Pyreos, mLED, Sphere Medical Holding, Genosis, Mirada Solutions, NextGen Sciences, e-San and Bioglan Pharma. She is currently a non-executive director of Scientific Digital Imaging (where she chairs the audit committee), Spectrum General in connection with the Rainbow Seed Fund and Lumacron.
Dr Val Corrigall
Group Discovery Leader
Dr. Val Corrigal was the co-founder of Immune Regulation (prior to its acquisition by Peptinnovate) and was previously in the Department of Academic Rheumatology, King’s College London specialising in immunology. Dr. Corrigal has published c.100 papers on RA, immunology and inflammation. She has worked in the Department of Rheumatology at King’s College Hospital and the Centre for Molecular and Cellular Biology of Inflammation. Her research laboratory was the first to discover the importance of the immune T-cell in the development of RA.
Dr. Jorge De Alba
Group Discovery Leader
Dr. Jorge De Alba (Group Discovery Leader) is a respiratory pharmacologist by background with 20 years of experience in drug discovery in academia and the pharmaceutical industry. Jorge started his career at GSK as a postdoctoral research scientist and subsequently joined the Respiratory Pharmacology group in the National Heart and Lung institute as part of the Academic Alternative Drug Initiative in collaboration with GSK. During this time, Jorge led the research programme investigating the role of sensory nerves and neuroinflammation in the Late Asthmatic Response. Jorge then joined Almirall where he set up and led the respiratory pharmacology group and was instrumental in developing the Company’s PK/PD animal models of respiratory disease, which delivered several clinical candidates. At Almirall, Jorge successfully led and managed several collaborative projects and was Almirall’s representative in the UBIOPRED, a prestigious international severe asthma consortium within the Innovative Medicine Initiative of the European Union. Following his time at Almirall, Jorge joined Evotec as VP of Anti-infectives leading the in vivo pharmacology operations and contributed to Evotec’s global strategy as a member of the in vivo pharmacology leadership team.
Dr. Donata Federici-Canova
Group Discovery Leader
Dr. Donata Federici-Canova (Group Discovery Leader) is a biotechnologist, with expertise on immunology studies and related inflammatory diseases. She has conducted post-doctoral research on the evaluation of anti-inflammatory properties of chaperonin-derived peptides at the Centre for Biochemical Pharmacology, WHRI, Queen Mary University of London. She holds a PhD in Molecular Medicine from the University of Eastern Piedmont, Italy.
Dr. Jeannette Watson
Head of Development
Dr. Jeannette Watson (Head of Development) is a pharmacologist by background and has worked in the pharmaceutical/biotechnology arena for over 25 years. A substantial amount of her career was spent at GSK and its legacy companies, whereby she successfully led CNS projects from target validation to early phase clinical development, through which she gained a good working knowledge of the drug development process.
During her time at GSK, Jeannette was also a key player in the establishment of human native tissue assays for pharmacological assessment of drug candidates in the target tissue. Jeannette then joined the small investor-funded biotech area whereby her first role was to lead the early phase clinical studies for Immune Targeting Systems, a company developing peptide vaccines for infectious diseases. During this period, Jeannette was instrumental in driving the preclinical development and Phase I assessment of a live virus that was subsequently approved for use in Phase II human challenge studies. Prior to joining Immune Regulation (formerly Peptinnovate) as Head of Development, Jeannette was Head of Clinical Project Management at Autifony Therapeutics. During this period, she helped build the clinical development team (both internal and external) to support the execution of the company’s clinical portfolio.
Dr. Ginny Norris
Interim Chief Medical Officer
Dr. Ginny Norris (Interim Chief Medical Officer) is a pharmaceutical physician with 16 years drug development experience across all phases (5 years specialist clinical pharmacology CR0, 11 years pharmaceutical industry), with a special interest in translational/early phase development. She has led a number of multidisciplinary development teams and clinical matrix teams providing strategic leadership to define and execute the overall development and/or clinical plans for assigned assets.
She also has extensive experience in clinical trial design and execution. This includes as an Investigator for numerous phase 1 (including FTIH) and phase 2a studies. She has experience in the development of small molecules (oral and inhaled) and biologics. She has considerable experience working in external collaborations for example with scientific experts, in-licensing and co-development partners. She has had interactions with major regulatory agencies (US, Europe, Japan, Korea) for purposes of scientific advice. Prior to joining Immune Regulation (formerly Peptinnovate), Ginny was Medical Director at RespiVert Ltd and she has held several senior positions in GSK, most recently as Senior Director, Translational Medicine, Immuno-inflammation TA. Before entering pharmaceutical medicine she spent 6 years in hospital medical practice.
Clinical Trial Support
Naomi Dugdale (Clinical Trial Support) has over 15 years’ experience of clinical project management within the biotech/pharmaceutical industry across a number of therapy areas, including immunological disorders, and across different phases of development. After obtaining a biological sciences degree from Birmingham University, Naomi started her career as a CRA at Merck whereby she was fundamental to the set up and monitoring of the Company’s clinical trials across several therapy areas. Naomi successfully progressed her career within Merck into the area of clinical trial management, directing both internal and external resource in order to meet Company objectives. Naomi, subsequently, moved to Biogen whereby she became operational lead for several of the Company’s clinical development programmes.